Jennifer Zachary sold $11M of MRK
EVP, General Counsel at Merck & Co., Inc.. 80,315 shares at an average of $133.46, traded Aug 12, 2026, filed Aug 13, 2026.
Score components
- +15RoleOfficer
- +25Trade size$10.7M at market
- +20Share of holdings soldSold 64% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000310158-26-000221, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | MOption exercise Common Stock | +41,494 | $117.89 | $4.9M | 112,391 | Aug 13, 2026 |
| Aug 12, 2026 | MOption exercise Common Stock | +13,433 | $84.71 | $1.1M | 125,824 | Aug 13, 2026 |
| Aug 12, 2026 | SOpen-market sale Common Stock | -80,315 | $133.46 | $11M | 45,509 | Aug 13, 2026 |
| Aug 12, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -41,494 | $0.00 | $0 | 0 | Aug 13, 2026 |
| Aug 12, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -13,433 | $0.00 | $0 | 0 | Aug 13, 2026 |
Related signals
Other insiders at Merck & Co., Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 60Notable | Merck & Co., Inc. | Chirfi Guindo EVP, Access, Policy & Comms | $1.4M 10,000 shares | -21% | |
| 65Notable | Merck & Co., Inc. | Richard R. DeLuca EVP&Pres, Merck Animal Heallth | $5.9M 45,320 shares | -29% | |
| 52Moderate | Merck & Co., Inc. | Richard R. DeLuca EVP&Pres, Merck Animal Heallth | $789k 6,050 shares | -4% | |
| 60Notable | Merck & Co., Inc. | Chirfi Guindo EVP, Access, Policy & Comms | $2.0M 15,000 shares | -24% | |
| 60Notable | Merck & Co., Inc. | David R. Maraldo EVP & Pres. MMD | $2.4M 18,706 shares | -76% | |
| 60Notable | Merck & Co., Inc. | David Michael Williams EVP,Chief Info&Digital Officer | $6.8M 52,847 shares | -146% | |
| 60Notable | Merck & Co., Inc. | Chirfi Guindo Chief Marketing Officer | $1.2M 10,000 shares | -14% | |
| 60Notable | Merck & Co., Inc. | Dean Y Li Executive VP & President, MRL | $1.2M 10,235 shares | -10% | |
| 60Notable | Merck & Co., Inc. | Chirfi Guindo Chief Marketing Officer | $1.2M 10,000 shares | -12% | |
| 60Notable | Merck & Co., Inc. | Jennifer Zachary EVP, General Counsel | $14M 121,573 shares | -128% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.